IPO - Cuprina Holdings (Cayman) LTD

Form Type: 424B4

Filing Date: 2025-04-10

Corporate Action: Ipo

Type: New

Accession Number: 000164117225003511

Filing Summary: Cuprina Holdings (Cayman) Limited is conducting its initial public offering (IPO) of 3,000,000 Class A Ordinary Shares at an initial offering price of US$4.00 per share. The shares have been approved for listing on the Nasdaq under the ticker symbol "CUPR." The company will have a total of 3,915,000 Class A and 14,085,000 Class B Ordinary Shares outstanding post-offering, with differing voting rights: Class A shares grant one vote each, while Class B shares grant ten votes and can be converted into Class A shares at the holder's option. The company has no public market for its shares prior to this offering, reflecting its status as an emerging growth company subject to reduced reporting regulations. The IPO will enable fundraising of approximately US$12 million before expenses and includes a provision for underwriters to purchase an additional 450,000 shares for over-allotments. Key business areas include biomedical and biotechnology sectors with a focus on chronic wound management and potential expansion into cosmeceuticals. The prospectus also highlights risks such as the company's history of operating losses and difficulties in achieving profitability. The document elaborates on the company’s structure, noting its incorporation as a Cayman Islands exempted company and its operational activities mainly in Singapore, Hong Kong, Saudi Arabia, Malaysia, and mainland China.

Document Link: View Document

Form Type: 8-A12B

Filing Date: 2025-04-09

Corporate Action: Ipo

Type: New

Accession Number: 000164117225003366

Filing Summary: Cuprina Holdings (Cayman) Limited has filed a Form 8-A12B for the registration of its Class A Ordinary shares with a par value of US$0.001 per share, intended to be listed on The Nasdaq Stock Market LLC. This filing is part of their registration process under the Securities Exchange Act of 1934, with the associated securities registration statement identified as 333-283643. The filing confirms that no exhibits are required since no other securities of the Registrant are currently registered on Nasdaq, and these shares are not being registered under Section 12(g) of the Act. The document was signed by David Quek Yong Qi, the Director and Chief Executive Officer, indicating the company is preparing for an initial public offering, as this registration is a prerequisite for trading on a public stock exchange. The filing date is April 9, 2025.

Document Link: View Document

Form Type: F-1/A

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: Update

Accession Number: 000149315225006654

Filing Summary: This document is an amendment to the registration statement for Cuprina Holdings (Cayman) Limited. It serves to file exhibit 23.1 and exhibit 99.7, and amends the exhibit index. No changes have been made to the core registration statement other than the revision of the cover page, the explanatory note, and Part II. The registration remains unchanged since the previous amendment (February 4, 2025). The registrant indicated that they are an emerging growth company, and have made indemnification provisions for their directors and officers. Recent sales of unregistered securities were detailed, and they asserted that they believe such sales are exempt from registration under the Securities Act. The filing provides a summary of various exhibits, including indemnity agreements and joint venture agreements. This amendment indicates readiness to commence public sales shortly after the effective date of this registration statement.

Document Link: View Document

Form Type: F-1/A

Filing Date: 2025-02-05

Corporate Action: Ipo

Type: New

Accession Number: 000149315225004913

Filing Summary: Cuprina Holdings (Cayman) Limited is conducting its initial public offering (IPO) by offering 3,750,000 Class A Ordinary Shares, with an expected price range of US$4.00 to US$4.50 per share. The IPO is contingent upon the approval of the Nasdaq Capital Market for listing under the symbol 'CUPR'. Prior to the offering, there was no public market for the shares. The company, incorporated in the Cayman Islands, operates in Singapore and other regions, focusing on biomedical innovation, particularly in chronic wound care. The firm offers medical devices, including its MEDIFLY brand, utilizing sterile blowfly larvae for Maggot Debridement Therapy. The company currently has plans for expansion into various markets, including the Middle East and mainland China, to cater to increasing demand for wound care products, driven by an aging population and rising chronic health issues. It is categorized as an emerging growth company and has experienced losses in its recent financial history, highlighting risks associated with its early-stage operations. The offering aims to raise approximately US$15.938 million before expenses, with a net revenue goal that takes into account underwriting commissions and proceeds allocated for growth and operations.

Document Link: View Document

Form Type: F-1/A

Filing Date: 2025-01-07

Corporate Action: Ipo

Type: Update

Accession Number: 000149315225001095

Filing Summary: Cuprina Holdings (Cayman) Limited is amending its registration statement for an initial public offering (IPO) of 3,750,000 Class A Ordinary Shares. The anticipated price range for the shares is between US$4.00 and US$4.50, with an initial public offering price set at US$4.25, amounting to total proceeds of approximately US$15.94 million before expenses. The IPO is dependent on Nasdaq approving the listing of these shares under the symbol 'CUPR'. Prior to the offering, the company will have a total of 3,915,000 Class A and 14,085,000 Class B Ordinary Shares outstanding. Each Class B share holds 10 votes and is convertible into Class A shares. The document also highlights the company's current operations in Singapore and projected expansion plans in various regions, focusing on biomedical and biotechnology products for chronic wound management. The company is classified as an emerging growth company and is benefitting from reduced public company reporting requirements. The prospectus outlines various risks and the competitive landscape of their business, emphasizing the innovative nature of their product portfolio, industry partnerships, quality management certifications, and anticipated significant market demand due to demographic trends favoring chronic wound care products.

Document Link: View Document